About: Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray
Creator	Jain, Aarti Tai, Sheldon Felgner, Philip Milton, Donald Adenaiye, Oluwasanmi Al Jasinskas, ) Davies, Huw Filbert, ) Khan, Saahir Nakajima, Rie Obiero, Joshua Ramiro De Assis, Rafael
Source	BioRxiv; Medline; PMC
abstract	The current practice for diagnosis of SARS-CoV-2 infection relies on PCR testing of nasopharyngeal or respiratory specimens in a symptomatic patient at high epidemiologic risk. This testing strategy likely underestimates the true prevalence of infection, creating the need for serologic methods to detect infections missed by the limited testing to date. Here, we describe the development of a coronavirus antigen microarray containing immunologically significant antigens from SARS-CoV-2, in addition to SARS-CoV, MERS-CoV, common human coronavirus strains, and other common respiratory viruses. A preliminary study of human sera collected prior to the SARS-CoV-2 pandemic demonstrates overall high IgG reactivity to common human coronaviruses and low IgG reactivity to epidemic coronaviruses including SARS-CoV-2, with some cross-reactivity of conserved antigenic domains including S2 domain of spike protein and nucleocapsid protein. This array can be used to answer outstanding questions regarding SARS-CoV-2 infection, including whether baseline serology for other coronaviruses impacts disease course, how the antibody response to infection develops over time, and what antigens would be optimal for vaccine development.
has issue date	2020-03-25(xsd:dateTime)
bibo:doi	10.1101/2020.03.24.006544
bibo:pmid	32511324
has license	no-cc
sha1sum (hex)	dacf3c63b879b66337f5994061bf7bf97d093264
schema:url	https://doi.org/10.1101/2020.03.24.006544
resource representing a document's title	Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray
has PubMed Central identifier	PMC7239054
has PubMed identifier	32511324
schema:publication	bioRxiv
resource representing a document's body	covid:dacf3c63b879b66337f5994061bf7bf97d093264#body_text
is schema:about of	named entity 'reactivity' named entity 'immunologically' named entity 'antibody' named entity 'protein' named entity 'specimens' named entity 'testing' named entity 'TO DETECT' named entity 'PRIOR TO' named entity 'SEROLOGIC' named entity 'PRELIMINARY STUDY' named entity 'SYMPTOMATIC' named entity 'STRAINS' named entity 'ANTIGEN' named entity 'CONTAINING' named entity 'DOMAIN' named entity 'METHODS' named entity 'SARS-COV' named entity 'PROTEIN ' named entity 'EPIDEMIC' named entity 'CORONAVIRUSES' named entity 'human' named entity 'patient' named entity 'array' named entity 'common' named entity 'disease' named entity 'SARS-CoV-2' named entity 'study' named entity 'develops' named entity 'SARS-CoV' named entity 'response' named entity 'nasopharyngeal' named entity 'high' named entity 'nucleocapsid' named entity 'SARS-CoV-2' named entity 'antigenic' named entity 'infection' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'cross-reactivity' named entity 'SARS-CoV-2 pandemic' named entity 'nucleocapsid protein' named entity 'SARS-CoV-2' named entity 'Serologic' named entity 'Human Coronaviruses' named entity 'coronavirus' named entity 'MERS' named entity 'coronavirus' named entity 'nasopharyngeal' named entity 'influenza virus' named entity 'influenza virus' named entity 'viruses' named entity 'antibodies' named entity 'H5N1' named entity 'antigens' named entity 'antigens' named entity 'F-test' named entity 'infection' named entity 'humoral response' named entity 'antibodies' named entity 'antigens' named entity 'cross-reactivity' named entity 'CC-BY-ND' named entity 'R Foundation' named entity 'H1N1' named entity 'antigen microarray' named entity 'cross-reactive' named entity 'antigens' named entity 'RBD' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software